Companies covered: GBS Inc. (NASDAQ:GBS), BriaCell Therapeutics Corp. (NASDAQ:BCTX), BioLineRx Ltd. (NASDAQ:BLRX), Achieve Life Sciences (NASDAQ:ACHV), Pfizer, Inc. (NYSE:PFE), GlaxoSmithKline PLC (NYSE:GSK), Dr. Reddy's Laboratories Ltd (NYSE:RDY), Alpha Cognition Inc. (OTCMKTS:ACOGF), Epizyme, Inc. (NASDAQ:EPZM), Turning Point Therapeutics Inc. (NASDAQ:TPTX), Ipsen ADR (OTCMKTS:IPSEY), Bristol-Myers Squibb Company (NYSE:BMY), Argenx SE (ADR) (NASDAQ:ARGX), IVERIC bio Inc. (NASDAQ:ISEE), Blueprint Medicines Corp. (NASDAQ:BPMC), Intellia Therapeutics Inc. (NASDAQ:NTLA), Verve Therapeutics Inc. (NASDAQ:VERV), Beam Therapeutics Inc. (NASDAQ:BEAM), 2Seventy Bio Inc. (NASDAQ:TSVT), Cogent Biosciences Inc. (NASDAQ:COGT), Gilead Sciences, Inc. (NASDAQ:GILD), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Gain Therapeutics Inc. (NASDAQ:GANX), Astria Therapeutics Inc. (NASDAQ:ATXS), Viracta Therapeutics Inc. (NASDAQ:VIRX), Oncternal Therapeutics, Inc. (NASDAQ:ONCT), United Therapeutics Corporation (NASDAQ:UTHR), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Arcellx Inc. (NASDAQ:ACLX), F-Star Therapeutics Inc. (NASDAQ:FSTX), Seagen Inc. (NASDAQ:SGEN), Merck & Company, Inc. (NYSE:MRK), CRISPR Therapeutics AG (NASDAQ:CRSP), Global Blood Therapeutics (NASDAQ:GBT), Krystal Biotech (NASDAQ:KRYS), bluebird bio, Inc. (NASDAQ:BLUE), Adaptimmune Therapeutics plc (NASDAQ:ADAP), Equillium Inc. (NASDAQ:EQ), RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI), Adial Pharmaceuticals Inc. (NASDAQ:ADIL), Veru Inc. (NASDAQ:VERU), NLS Pharmaceutics AG (NASDAQ:NLSP), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Atreca Inc. (NASDAQ:BCEL), Dare Bioscience (NASDAQ:DARE), Organon & Co. (NYSE:OGN), Gamida Cell Ltd. (NASDAQ:GMDA), Inhibikase Therapeutics, Inc. (NASDAQ:IKT), Geron Corporation (NASDAQ:GERN)
